Best Peptides for Sleep and Recovery: A Research Comparison

Peptide research on sleep architecture and post-exertion recovery is the thinnest evidence base in this buyer-intent series. The three compounds most commonly used are DSIP, Selank, and MOTS-c, and none of them have the trial-depth of the GLP-1 or GH-secretagogue classes. This article is correspondingly more qualified: it explains what each compound does, where the literature is strong and where it is thin, and how researchers typically use them.

Honest positioning: if the research question is specifically sleep architecture, DSIP is the research tool with the most-cited (though not deepest) literature. If the question is post-exertion muscle recovery, MOTS-c is the compound with the strongest recent evidence. Selank sits at the overlap of cognition and sleep; its primary home is the cognitive-function article.

Comparison at a glance

How to choose between them

This article’s honest framing starts with identifying which axis the research is actually on.

If the research question is sleep architecture (NREM duration, REM onset, sleep efficiency via polysomnography), DSIP is the primary tool. The Kovalzon 2006 J Neurochem review is the most-cited contemporary summary, and its honest title (“a still unresolved riddle”) frames the evidence base accurately ¹. Schoenenberger’s earlier characterisation work from the 1984 Eur Neurol paper remains the foundational reference for the compound’s properties ².

If the research question is post-exertion muscle recovery or metabolic recovery from stress, MOTS-c is the more evidence-supported choice. Reynolds and colleagues’ 2021 Nature Communications paper positioned it as an exercise-induced regulator of age-dependent physical decline, with measurable effects on muscle homeostasis ⁴.

If the research question spans anxiolytic, cognitive, and sleep-quality endpoints together, Selank is occasionally used, particularly in protocols drawing on Russian-language research literature ³. For a pure cognitive focus, see the cognitive-function article.

DSIP

DSIP (delta-sleep-inducing peptide) is a nonapeptide originally isolated from rabbit cerebrospinal fluid in the 1970s. It takes its name from its effect in early research on EEG-measured delta-wave sleep activity. Its mechanism is incompletely characterised: proposed actions include modulation of NREM sleep architecture, attenuation of stress-induced HPA-axis activation, and effects on chronic pain endpoints. No specific receptor has been unambiguously identified for its signalling.

Where the literature stands: Schoenenberger’s 1984 Eur Neurol paper is the canonical characterisation reference ². Kovalzon and Strekalova’s 2006 J Neurochem review is the clearest contemporary consolidation of the evidence base and is openly titled “a still unresolved riddle” ¹. Most of the supportive data is preclinical; human clinical work is sparse and often dated.

Why a researcher picks DSIP: research questions specifically about sleep-architecture modulation or stress-attenuation pathways, with clear-eyed acknowledgment that the evidence base is thinner than for most other peptides in the catalogue. Typical dosing is nightly SC (100–200 µg) ahead of sleep onset.

Selank

Selank is a synthetic heptapeptide analogue of the natural tetrapeptide tuftsin. Its primary research endpoints are anxiolytic effects (without the sedation or dependence liability of benzodiazepines) and nootropic activity. Mechanism involves modulation of GABAergic and enkephalinergic systems, and elevation of BDNF expression in hippocampus. Russian clinical registration exists for anxiety-related indications.

Where the literature stands: Kolomin and colleagues’ transcriptomic work on Selank in rat hippocampus and spleen is representative of the mechanistic Russian research programme ³. Western clinical replication is limited.

Why a researcher picks Selank in a sleep context: when the research question involves sleep quality as a downstream endpoint of anxiety reduction, rather than sleep architecture as the primary target. Intranasal dosing (2–3× daily) is the standard route; 14-day on / 14-day off cycling is common.

MOTS-c

MOTS-c is a 16-amino-acid mitochondrial-encoded peptide that acts as a signalling molecule between mitochondria and the nucleus. It activates AMPK via the folate-methionine cycle and has measurable effects on insulin sensitivity, metabolic flexibility, and muscle homeostasis. Endogenous MOTS-c is exercise-induced.

Where the literature stands: Reynolds and colleagues’ 2021 Nat Commun paper established MOTS-c’s role in age-dependent physical decline and muscle recovery ⁴. It is the most-recently-published substantial evidence in this article.

Why a researcher picks MOTS-c in a recovery context: research questions specifically about post-exertion adaptation, mitochondrial recovery, or exercise-induced biomarker modulation. 3× weekly SC dosing fits naturally alongside training protocols.

Protocol considerations

Two cautions worth naming:

1. This evidence base is thinner than the other buyer-intent categories. Researchers should design protocols with appropriate hedging: smaller arms, shorter durations, clear primary endpoints. The compounds are useful tools, but the literature does not support confident predictions about outcome sizes in the way GLP-1 or GHS research does.
2. Route selection matters. DSIP is SC (nightly). Selank is intranasal (2–3× daily). MOTS-c is SC (3× weekly). A protocol combining all three involves coordinating three different routes and three different schedules; plan accordingly.

Where to order

All three compounds are supplied by Thailand Peptides from the Bangkok research desk. Same-week Thailand delivery, lab reports on request, WhatsApp ordering.

• Buy DSIP: 5 mg vials, ≥98% HPLC purity
• Buy Selank: intranasal research formulation, ≥98% HPLC purity
• Buy MOTS-c: 10 mg vials, ≥98% HPLC purity

For combined sleep-plus-recovery protocols, DSIP + MOTS-c is the more common pairing (two routes but non-overlapping schedules). Research desk will confirm bundled pricing in chat.